Next week, on May 31 in American and June 1 in Europe, we will be discussing the two major AKI studies looking at the timing of renal replacement therapy:
Look for a formal background post later this week.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies,
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
Next week, on May 31 in American and June 1 in Europe, we will be discussing the two major AKI studies looking at the timing of renal replacement therapy:
AKIKI https://t.co/HbpI0AkhPj
— Graham Abra, MD (@GrahamAbra) May 22, 2016
Vs
ELAINhttps://t.co/RVqRSDPm1c
Fight!
Look for a formal background post later this week.